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The 2014 Ebola outbreak in West Africa, primarily affecting Guinea, Sierra Leone, and
Liberia, has exceeded all previous Ebola outbreaks in the number of cases and in inter-
national response. Although infections only occur frequently in Western Africa, the virus
has the potential to spread globally and is classiﬁed as a category A pathogen that could
be misused as a bioterrorism agent. This review aims (i) to discuss the latest data to aid
our current recommendations for the prevention and control of the Ebola virus infection,
(ii) to review its pathophysiology as well as offering insights on the most current data
available about Ebola vaccine progress and potential use.1. Introduction
In today's world, it is important that we take careful
consideration of relevant issues that can pose a threat to our
overall well-being. Thus, as humans and caretakers of this
world, we must carefully examine and research health issues;
particularly viruses, as they can be quite deadly. Researching
about viruses can allow us to gain a better understanding of how
viruses function so that better treatment options and preventative
measures can be undertaken. This paper will examine one such
virus that has developed over the course of the past year causing
several fatalities: the Ebola virus. In December of 2013, the ﬁrst
case of the Ebola virus was identiﬁed. On December 26, 2013, a
2-year-old child in the remote Guinean village of Meliandou
presented to the hospital complaining of fever, black stools, andvomiting [1]. Two days after presentation, the patient passed
away and within the next few months thousands of people
living in the surrounding areas also started to experience
similar symptoms within Guinea, Liberia, and Sierra Leone [1].
The mysterious illness, as described by the local populations,
was soon after identiﬁed as the Ebola virus infection, which
was prevalent 30 years ago. In 1976, a new ﬁlovirus was
identiﬁed in Zaire (now the Democratic Republic of Congo),
and was named Ebola after the River Ebola in the Democratic
Republic of Congo. The mortality rate caused by the virus
was around 90% [1]. In this article, we will review the
virology and epidemiology behind the Ebola virus along with
topics such as the diagnostic procedures, as well as ways in
which the virus is transmitted and the potential treatment
options.
2. Classiﬁcation of Ebola virus disease
Ebola virus is a nonsegmented, negative-sense, single-
stranded RNA virus that resembles rhabdoviruses and para-
myxoviruses in its genome organization and replication mech-
anisms. It is a member of the family Filoviridae, taken from the
Latin ‘ﬁlum’, meaning thread-like, based upon their ﬁlamentousess article under the CC BY-NC-ND
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Ebola genuses including Zaire (EBOV), Sudan, Bundibugyo,
Tai Forest and Reston [2]. Out of the ﬁve different species of the
Ebola virus, only the Bundibugyo, Zaire, and Sudan species
have been responsible for the recent Ebola outbreaks over the
course of the past year [3]. The Bundibugyo virus emerged in
Uganda in 2007, causing an outbreak of Ebola virus disease
with a lower case-fatality rate (approximately 30%) that is
typical for the Zaire and Sudan viruses. Sequencing has shown
that the agent is most closely related to the Ivory Coast species
[4]. The Zaire virus, since it was ﬁrst recognized in 1976, has
caused multiple large outbreaks in Central Africa, with
mortality rates ranging from 55% to 88% [5]. It is the main
causative agent of the West African epidemic [5]. The Sudan
virus has been associated with a case-fatality rate of approxi-
mately 50% in four epidemics: two in Sudan in the 1970s, one in
Uganda in 2000, and another in Sudan in 2004 [6]. The Tai
Forest Virus, was initially identiﬁed from a patient and a
chimpanzee in 1994 in the Ivory Coast [1]. The ﬁfth Ebola
species, the Reston virus, differs markedly from the others,
because it is apparently maintained in an animal reservoir in
the Philippines and has not been found in Africa [7]. This type
was ﬁrst identiﬁed within the United States during the time of
1989 and 1990 and was followed by a similar outbreak in
Italy [1].
Perhaps the greatest mysteries regarding the ﬁloviruses are
the identity of their natural reservoir(s) and the mode of trans-
mission to wild apes and humans [8]. The exact location, origin
and natural reservoir of the Ebola virus remains uncertain,
however it is believed that the virus is zoonotic and fruit bats
may be the cause of its dissemination [1]. In accordance to the
above, Tosh and Sampathkumar also agree that the exact
origins, locations and natural reservoirs are not explicitly
known but do seem likely to be linked to a zoonotic disease
[3]. Furthermore, it has also been examined that members of
the primate family, such as monkeys and apes, can also get
infected with the Ebola virus and more importantly act as
intermediate hosts of the virus [1,3]. As such in certain cases if
people are in contact with or have perhaps eaten the infected
reservoir of an infected animal, they could be infected in turn.
However, with that being said and as summarized later in this
article, in order for Ebola to be transmitted in any large-scale
person–person transmission, the virus would have to be spread
through blood or other bodily ﬂuids including urine, saliva,
sweat, feces, vomitus, breast milk, and semen as well as
contaminated objects such as needles and syringes [1].
Moreover, the Ebola virus is not transmitted through air or
water or food in general [1]. In addition to this, the infectivity
only occurs once there is an onset of the symptoms [1]. Thus,
transmission of the Ebola virus is relatively low in the early
stages of the virus. In contrast with the early stages of the
virus, the later stages can cause much of a strain because the
amount of viral particles originating from the patient in
question is extremely high and will most easily effect a person
who is not taking the proper preventative measures [1].
3. Epidemiology
Since its ﬁrst occurrence in 1976, the Ebola virus has thus
manifested itself into ﬁve different subtypes and thus has spread
into several areas of Africa. It has been mentioned, through
historical evidence and recent studies, that the Ebola virus tendsto break out in small villages that are in close proximity to or are
perhaps located in tropical rainforests [3]. This can be further
supported by the fact that certain types of Ebola viruses,
including EBOV and Sudan virus, can be carried in members
of the primate family that tend to reside in rainforests.
Although all previous Ebola outbreaks occurred in Africa, the
epidemic began in the West African nation of Guinea in late
2013 and was conﬁrmed by the World Health Organization in
March 2014 [9]. As mentioned above, the initial case was a two-
year-old child who developed fever, vomiting, and black stools,
without other evidence of hemorrhage [9]. The outbreak
subsequently spread to Liberia, Sierra Leone, Nigeria, Senegal,
and Mali [10]. Areas that have been drastically hit by the
Ebola virus are Guinea, Sierra Leone, Nigeria, and Liberia [3].
In less than one year, the Ebola outbreak managed to develop
into 9216 cases from an initial amount of 86 cases and 4555
deaths from an initial amount of 60 deaths [3]. The magnitude
of the outbreak, especially in Liberia and Sierra Leone, has
probably been underestimated, due in part to individuals with
Ebola virus disease being cared for outside the hospital setting
[11]. As of January 21, 2015, the cumulative number of
probable, suspected, and laboratory-conﬁrmed cases attributed
to Ebola virus is 21724, including 8641 deaths [12]. In Guinea,
Liberia, and Sierra Leone, the number of new cases has
decreased as appropriate resources to isolate and treat patients
have become increasingly available [12]. In the parts of West
Africa where transmission was limited (Senegal, Nigeria, and
Mali), the disease appears to have been eliminated [12–14].
4. Pathogenesis and transmission
The Ebola virus enters the host in question through mucosal
surfaces, a skin defect, or perhaps by a parental introduction [1].
After entering the body through mucous membranes, breaks in
the skin, or parenterally, Ebola virus infects many different
cell types. Macrophages and dendritic cells are probably the
ﬁrst to be infected; ﬁloviruses replicate readily within these
cells, causing their necrosis and releasing large numbers of
new viral particles into extracellular ﬂuid [15]. It has also been
studied that the virus has the capability of disseminating to
regional lymph nodes through the lymphatic system along
with the liver and spleen via blood [1]. The detailed
pathogenesis of Ebola virus disease is illustrated in Figure 1 [16].
Epidemics of Ebola virus disease are generally thought to
begin when an individual becomes infected through contact with
the meat or body ﬂuids of an infected animal. Once the indi-
vidual becomes ill or dies, the virus then spreads to others who
come into direct contact with the infected individual's blood,
skin, or other body ﬂuids. However, it should be noted that for
any large-scale human transmittance to occur there must be a
direct contact of mucous membranes, or broken skin with
bloody or bodily ﬂuids of an infected person [1]. Such
transmission can involve any contact by the form of blood or
bodily ﬂuids including but not limited to urine, saliva, sweat,
feces, vomitus, breast milk, and semen, as well as via
contaminated objects like needles and syringes [1]. There are
no reported cases of Ebola virus being spread from person to
person by the respiratory route [17]. However, laboratory
experiments have shown that Ebola virus released as a small-
particle aerosol is highly infectious for rodents and nonhuman
primates [18]. Healthcare workers may therefore be at risk of
Ebola virus disease if exposed to aerosols generated during
Figure 1. Model of Ebola virus pathogenesis in primates [16].
(a) Virus spreads from the initial infection site to regional lymph nodes, liver and spleen. At these sites, the virus infects tissue macrophages (including
Kupffer cells) and dendritic cells. Soluble factors released from virus-infected monocytes and macrophages act locally and systemically. Release of che-
mokines from these virus-infected cells recruits additional macrophages to sites of infection, making more target cells available for viral exploitation and
further amplifying the dysregulated host response. Although none of these viruses infects lymphocytes, their rapid loss by apoptosis is a prominent feature of
disease. The direct interaction of lymphocytes with viral proteins cannot be discounted as having a role in their destruction, but the marked loss of lym-
phocytes is likely to result from a combination of factors including virus infection of dendritic cells and release of soluble factors from virus-infected
monocytes and macrophages. For example, virus infection of dendritic cells impairs their function by interfering with the up-regulation of costimulatory
molecules, which are important in providing rescue signals to T lymphocytes. Additionally, release of soluble factors from infected monocytes and mac-
rophages results in deletion of lymphocytes, both directly by release of mediators such as nitric oxide and indirectly by contributing to up-regulation of
proapoptotic proteins such as Fas and TRAIL. The coagulation abnormalities vary in nature and magnitude among the VHFs. For example, Ebola virus
induces the overexpression of tissue factor, which results in activation of the clotting pathway and the formation of ﬁbrin in the vasculature. In contrast,
coagulation disorders are less marked in Lassa fever, and impairment of endothelial function contributes to edema, which seems to be a more prominent
ﬁnding in Lassa fever than in other VHFs. (b) The hemodynamic and coagulation disorders common among all of the VHFs are exacerbated by infection of
hepatocytes and adrenal cortical cells. Infection of hepatocytes impairs synthesis of important clotting factors. At the same time, reduced synthesis of al-
bumin by hepatocytes results in a reduced plasma osmotic pressure and contributes to edema. Impaired secretion of steroid-synthesizing enzymes by
hemorrhagic fever virus-infected adrenal cortical cells leads to hypotension and sodium loss with hypovolemia. Macular rashes are often seen in VHFs.
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occur when appropriate personal protective equipment is not
available or is not properly used, especially when caring for a
severely ill patient who is not recognized as having Ebola
virus disease. Infected patients are not typically contagious
during the incubation period, and become so only when they
are actually ill. During severe illness with Ebola, blood, sweat,
feces, and vomit are highly infectious [19]. Therefore, it is also
thought that healthcare workers who do not follow proper
preventative measures are at the highest risk for secondary
infection [3]. Moreover, it has also been studied that the route
of transmission has an effect on the outcome of the virus [19].
In the early EBOV outbreak in 1976, case fatality rates after
transmission by injection was 100% versus 80% in contact
exposure cases [19]. This has also been conﬁrmed in non-
human primate models, which show a faster progression of the
Ebola virus through injection versus those received by other
transmission methods [19].5. Clinical manifestation
Patients with Ebola virus disease have an incubation period of
2–21 d with a mean ranging from 4 to 10 d [1,3,19]. Most cases of
Ebola virus disease begin with the abrupt onset of ﬂu-like
symptoms including fever, chills, and myalgia [1,3,19]. Once
further developed, the ﬂu-like symptoms may progress into
vomiting and diarrhea [19]. In addition to this further progression,
the Ebola virus continues to transpire thereby effecting multiple
systems within the body including gastrointestinal, respiratory,
vascular, and neurological systems [1]. Such symptoms involved
with the above mentioned systems can include nausea,
vomiting, abdominal pain, diarrhea, chest pains, coughing,
postural hypertension, edema, as well as headache, confusion,
and possibly coma [1,19]. Approximately 5–7 d after the initial
symptoms have transpired, a diffuse erythematous, nonpruritic
maculopapular rash begins to develop along with severe
abdominal pains, severe watery diarrhea, nausea and vomiting
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illness and include petechiae, ecchymoses, uncontrolled oozing
from venepuncture sites, mucosal hemorrhages, and post-
mortem evidence of visceral hemorrhagic effusions [1]. The
hemorrhages can be quite severe but affect only half of the
patients infected by Ebola [1]. Patients that present severe
clinical signs early on during the course of the infection tend to
die typically within 6–16 d with hypovolemic shock and multi-
organ failure [1]. Those who do not possess fatal symptoms such
as a fever for several days, tend to recover within 6–11 d with a
prolonged period of weakness, fatigue, poor appetite, and
failure to regain weight that was lost during the illness [3]. As
suggested by Goeijenbier et al., there has not been much
scientiﬁc evidence to support the long-term complications of the
Ebola virus for those who have successfully recovered; however,
available literature suggests that recovered patients of Ebola could
potentially develop disorders such as recurrent hepatitis, myelitis,
prolonged hair loss, psychosis and uveitis [19].
6. Diagnosis
Although there are no approved speciﬁc therapies for Ebola
virus disease, it is essential to make the diagnosis as early as
possible, in order to initiate supportive measures before the
development of irreversible shock and to institute infection con-
trol procedures. From what has been gathered about the previ-
ously mentioned symptoms of Ebola, it can be surmised that its
early symptoms have the power tomimic other diseases; the Ebola
virus usually presents as an acute viral prodrome and many dif-
ferential diagnoses should be considered, such as malaria, typhoid
fever, yellow fever and meningococcal meningitis, which are also
endemic diseases in Africa [1]. The approach to evaluate patients
with possible Ebola virus disease depends uponwhether or not the
individual displays appropriate signs and symptoms, how likely it
is that the exposure will result in disease, and when the exposure
occurred. According to Chan and Tseng, laboratory diagnosis of
Ebola should be performed in a well-equipped laboratory with
up to a level 4 biosafety for bio-contaminant facilities for viral
culturing [1]. Furthermore, key symptoms that should be a deﬁnite
sign of the presence of the Ebola virus include the following: (1)
acute febrile illness (38 C) (2) headache, myalgia, nausea,
vomiting, diarrhea and abdominal pain, (3) bleeding with
unknown reason, and (4) sudden death with unknown reason
[1]. In addition to these symptoms, laboratory conditions should
be reﬂective of the following: (1) clinical specimen (throat swab
or skin biopsy) that were isolated and identiﬁed as Ebola virus,
(2) clinical specimen that show positive by reverse transcription
polymerase chain reaction, and (3) serology (enzyme link
immunosorbent assays, IgM and IgG) positive [1]. Lastly,
epidemiologic conditions, with any of the following 21 d before
onset of symptoms: (1) history of travel from or living in the
endemic area of EVD, (2) exposure of blood, body ﬂuids or
discharge pollutants from possible or deﬁned cases, (3) history
of contact with bats, rodents, or primates in endemic area of
EVD, and (4) operate the specimen of EVD in a laboratory [1].
7. Treatment
According to Chan and Tseng, there is no standard treatment
present for the Ebola virus [1]. However, wherever outbreak is
identiﬁed, similar strategies and treatment methods are
undertaken. Whenever possible, patients with Ebola virusdisease should receive care in designated treatment centers and
by clinicians trained to care for such patients [20]. Treating
patients with Ebola requires a multidisciplinary approach [21].
All healthcare workers involved in the care of infected or
potentially infected patients should use infection control
precautions, including the proper use of personal protective
equipment. Currently, main strategies to deal and treat with
the Ebola virus are symptomatic and supportive care which
include ﬂuid and electrolyte preservation, maintaining oxygen
saturation and blood pressure, and treating complication such
as secondary infections [1,22]. Once identiﬁed that the patient
is in fact infected, then they must be isolated and treated
promptly according to the symptoms exhibited [19,22]. If
identiﬁed early on, the best treatment option which can result
in a higher rate of survival is to replace lost ﬂuid [3].
Additional supportive measures may include symptomatic
management of fever, pain (abdominal, joint, muscle), nausea,
vomiting, and diarrhea. The use of anti-diarrheal agents may
also decrease ﬂuid and electrolyte losses [23]. Patients with
coagulopathy and bleeding may require blood. Renal
replacement therapy may be needed to manage severe acute
kidney injury in the setting of shock [24]. In some case series,
empiric antimicrobial therapy was used for all patients at the
time of initial presentation, or for patients who had evidence
of gastrointestinal dysfunction, even if clinical evidence of
bacterial sepsis was absent [25]. However, data are currently
lacking to justify this approach.
According to the World Health Organization, since the
severity and magnitude of the current outbreak of the Ebola
virus is quite grand, it is ethical to use experimental drugs for
treatment and prevention [19]. The urgent need for effective
treatments has thus accelerated the evaluation of several
experimental therapies that had been developed speciﬁcally to
treat or prevent Ebola or Marburg virus infection, but have
only been tested in laboratory animals. Several treatment
options have been available and in most part such treatment
options have transpired because initial symptoms tend to vary
from patient to patient. One of the experimental drugs used for
treatment is known as Zmapp, developed by Mapp
Biopharmaceutical, Inc., is a combination of three humanized
murine antibodies generated by Ebola virus infected mice, and
subsequently produced in tobacco plants [1]. In a study carried
out to experiment the viability of Zmapp, 43% of infected
mice survived with the Zmapp treatment [1]. Other Ebola-
speciﬁc agents in development include TKM-Ebola (a short
interfering RNA molecule), phosphorodiamidate morpholino
oligomers (a type of antisense oligonucleotide), and BCX4430
(a nucleoside analog). In addition, two antiviral agents with anti-
Ebola virus activity in cell culture or laboratory animals (favi-
piravir and brincidofovir) that have been used in patients with
Ebola virus disease, are also currently being evaluated [26,27].
Two other antiviral drugs that are used in the treatment of
Ebola are ribavirin and lamivudine [1]. However, ribavirin has
not been a recommended treatment option due to its adverse
effects and with lamivudine there wasn't any signiﬁcant
survival rate [1,22].
Another treatment option is convalescent therapies. Conva-
lescent therapies are treatment options that utilize plasma from
recovered Ebola patients [1]. In 1976, the treatment had been
used for a woman with EVD in Zaire. Initially, her symptoms
were improved but she eventually passed [1]. Similar to the
experimental drug Zmapp, convalescent therapies are a
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been implemented including antiviral drugs and vaccines.
Preventing the transmission remains the way of controlling
the infection. Several concurrent strategies should be employed
to prevent the spread of Ebola virus. Strict infection control
measures and the proper use of personal protective equipment
are essential to prevent transmission to healthcare workers. In
addition, individuals who have been exposed to Ebola virus
should be monitored, so that they can be identiﬁed quickly if
signs and symptoms develop. Other preventive measures may
eventually include vaccination. However, at present, there are no
approved vaccines to prevent Ebola virus disease. Two vaccines
have been in use as a treatment option for Ebola; cAd3-EBOV
(cAd3) and rVSVDG-EBOV-GP (rVSV) [1]. Both of these
vaccines are still under investigation for their viability.
8. Conclusions and the way forward
Overall, it can be surmised from the discussion presented
above that the Ebola virus disease may be a deadly and extensive
disease that requires our utmost attention. Over the course of the
past year, the Ebola virus has spread like wildﬁre in Western
Africa. In addition to this, it has also managed its way across to
North America. As such it is very important that we carefully
examine Ebola as it is a virus that is constantly changing and
getting ever so stronger. Such an epidemic has most deﬁnitely
shaken up the scientiﬁc world causing research in the ﬁeld of
medicine to heighten in order to not only learn more about the
virus itself but also study preventative measures as well as
treatment options. As mentioned in this review, the virus can
reﬂect varying symptoms as it has the potential to affect multiple
systems of the body including gastrointestinal, respiratory,
vascular, and neurological systems. As such various treatment
options are underway to deal with the virus in the best possible
way so as to reduce the risk of fatality. Due to the virus's severity
and magnitude, the World Health Organization has stated that
experimental drugs are ethical and can be used as a form of
treatment. Other options have been put into place including
vaccines, antiviral drugs, and convalescent therapies; however,
each of them seem to either have their own set of issues or are
perhaps considered a relatively new treatment method and
require further consideration and examination.
In conclusion, the world has been faced with quite a struggle
and further research in the medical ﬁeld must be carried out at a
continuous pace. With such a deadly virus on the rise, it is
pertinent that safety measures and health precautions be advised
and followed for the sake of humanity. Next steps should
involve not only research incentives to learn more about Ebola
and how to deal with it but to raise awareness of it for the sake of
the public. People should learn more about Ebola and its po-
tential. Moreover, the public should be given access to ways in
which they can learn more about Ebola and should be able to
know what the signs and symptoms are so as to seek medical
attention as needed. With that being said, much work has been
done thus far in order for the public to gain more knowledge
about Ebola. Furthermore, it is essential that we point out the
admirable work that is being done in places in Western Africa to
medically assist those who have been diagnosed with Ebola as
they are risking their own health for the safety of others. We
must adamantly continue to learn more the Ebola virus, carry out
research studies to examine its roots and strive to develop
treatment options. In addition to this, it should also be wise topoint out that such areas that are affected by the Ebola virus and
those areas where outbreaks tend to occur are in smaller
impoverished area. As such it is extremely important that we
identify these areas and provide adequate medical attention as
swiftly as possible [1,19].
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